Información del artículo
Objetivos
Evaluar el efecto del etofibrato de liberación sostenida en las concentraciones de lipoproteína(a) [Lp(a)] plasmática en pacientes con concentraciones superiores a 300 mg/l después de 3 meses de dieta tipo etapa I del National Colesterol Education Program (NCEP)
MétodoDe un total de 112 pacientes examinados en la consulta externa de dislipidemias del Hospital Hermanos Ameijeiras, La Habana, se seleccionó a 20 pacientes (10 varones y 10 mujeres) que presentaron concentraciones séricas de Lp(a) superiores a 300 mg/l después de 3 meses de dieta hipolipemiante etapa I del NCEP. Se administró a los pacientes seleccionados etofibrato, 500 mg/día, durante 24 semanas. Se determinaron las concentraciones de colesterol y triglicéridos totales, de colesterol asociado a las lipoproteínas de baja (cLDL) y alta (cHDL) densidad y las de Lp(a) antes y a las 4, 12 y 24 semanas del tratamiento
ResultadosSe observaron reducciones significativas de colesterol, triglicéridos y cLDL y aumentos de cHDL en cada tiempo analizado en relación con el valor basal. Las concentraciones séricas de Lp(a) se redujeron significativamente (p < 0,01) con la administración de etofibrato: 856 mg/l en situación basal, 617 mg/dl a la cuarta semana después del tratamiento, 594 mg/l a la 12.a semana y 604 mg/l a la 24.a semana. La reducción ya fue significativa desde la cuarta semana de tratamiento y se mantuvo así hasta la 24.a semana. En 4 de los 20 pacientes, cuyas concentraciones basales de Lp(a) fueron las más bajas de todo el grupo, se observó un aumento significativo (p < 0,001) de la Lp(a) en la semana 24 de tratamiento (desde 559 a 636 mg/l)
ConclusionesEl etofibrato de liberación retardada, a dosis de 500 mg/día, redujo las concentraciones de Lp(a) en más del 30%, en relación a su valor basal, después de 4 semanas de su administración y mantuvo esta tendencia durante las 24 semanas de control en los pacientes con las concentraciones más elevadas; en los pacientes con concentraciones más bajas (aunque superiores a 300 mg/l) se incrementó ligera, pero significativamente la Lp(a). Estos efectos del etofibrato en la concentración de Lp(a) no han sido descritos con anterioridad
Palabras clave:
Lipoproteína(a)
Etofibrato
Objectives
To evaluate the effect of a sustainedrelease form of etofibrate on the lipoprotein(a) [Lp(a)] concentration in patients showing Lp(a) concentrations higher than 300 mg/l after a 3- month period of NCEP National Cholesterol Education Program (NCEP) step-I diet
MethodsAmong 112-screened patients, 20 (10 female and 10 male) were selected when their Lp(a) concentrations were higher than 300 mg/l after 3-month period on NCEP step type-I diet. All selected patients received etofibrate retard (500 mg/day) during 24 weeks. Total cholesterol and triglycerides and cholesterol associated to low (LDLc) and high density (HDLc) lipoproteins, as well as Lp(a) concentrations were measured before and after 4, 12 and 24 weeks of etofibrate therapy
ResultsSignificant decrease respect to pretreatment values was observed for total cholesterol and triglyceride and for low (LDLc) and high (HDLc) cholesterol concentrations after etofibrate therapy. Lp(a) concentrations decreased significantly (p < 0.01) from 856 to 617 mg/l (after 4 weeks of etofibrate), 594 (after 12 weeks) and 604 (after 24 weeks). Significant reductions of Lp(a) occurred since week 4 of therapy. Four of the 20 treated patients, showed small, but significant (p < 0.001) increases (from 559 to 636 mg/l) of Lp(a) concentrations after etofibrate therapy; Lp(a) concentrations of these patients were the smallest among all the analyzed patients
ConclusionsExtended-release etofibrate at a dose of 500 mg/day reduced Lp(a) concentrations in a 30% after 4-weeks of therapy; the effect of etofibrate on Lp(a) concentrations extended until the end of therapy (at 24th week of treatment). Etofibrate reduced Lp(a) concentrations in patients showing higher Lp(a) concentrations; however, in patients showing smallest increases of Lp(a) a light, but significant, increase of Lp(a) was observed. These effects of etofibrate on Lp(a) concentrations are described for the first time
Key words:
Lipoprotein(a)
Etofibrate
El Texto completo está disponible en PDF
Bibliografía
[1.]
K.A. Berg.
A new serum type system in man. The Lp System.
Acta Pathol Microbiol Scand, 59 (1963), pp. 369-382
[2.]
A. Nasiff-Hadad, E. Anglés-Cano.
Lipoproteína(a): trombogénesis y aterogénesis.
Rev Cubana Hematol Inmunol Hemoter, 13 (1997), pp. 6-18
[3.]
J. Fan, H. Sun, H. Unoki, M. Shiomi, T. Watanabe.
Enhanced atherosclerosis in Lp(a) WHHL transgenic rabbits.
Ann N Y Acad Sci, 947 (2001), pp. 362-365
[4.]
T. Ichikawa, H. Unoki, H. Sun, H. Shimoyamada, S. Marcovina, H. Shikama, et al.
Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits.
Am J Pathol, 160 (2002), pp. 227-236
[5.]
M. Seed, F. Hoppichler, D. Reaveley, S. McCarthy, G.R. Thompson, E. Boerwinkle, et al.
Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.
N Engl J Med, 322 (1990), pp. 1494-1499
[6.]
J. Genest, J.L. Jenner, J.R. McNamara, J.M. Ordovas, S.R. Silberman, P.W.F. Wilson, et al.
Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease.
Am J Cardiol, 67 (1991), pp. 1039-1045
[7.]
A.G. Bostom, D.R. Gagnon, A. Cupples, P.W.F. Wilson, J.L. Jenner, J.M. Ordovas, et al.
A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study.
Circulation, 90 (1994), pp. 1688-1695
[8.]
E.J. Schaefer, S. Lamon-Fava, J.L. Jenner, J.R. McNamara, J.M. Ordovas, C.E. Davis, et al.
Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics coronary primary prevention trial.
Jama, 271 (1994), pp. 999-1003
[9.]
G.H. Dahlén, H. Stenlund.
Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance.
Clin Genet, 52 (1997), pp. 272-280
[10.]
S.M. Marcovina, M.L. Koschinsky.
Lipoprotein(a) as a risk factor for coronary artery disease.
Am J Cardiol, 82 (1998), pp. 57U-66
[11.]
A. Batalla, J.R. Reguero, G. Iglesias Cubero.
Plasma lipoprotein(a) and severity of angiographic coronary artery disease.
J Am Coll Cardiol, 33 (1999), pp. 590-591
[12.]
A. Fujino, T. Watanabe, H. Kunii, N. Yamaguchi, K. Yoshinari, Y. Watanabe, et al.
Lipoprotein(a) is a potential coronary risk factor.
Jpn Circ J, 64 (2000), pp. 51-56
[13.]
P. Uusimaa, K. Kervinen, A. Kesaniemi, K. Peukurinen.
Serum lipoprotein( a) level in relation to severity of coronary artery disease and coronary artery patency in acute myocardial infarction.
Heart Vessels, 16 (2002), pp. 37-41
[14.]
C.E. Scherle, A. Nasiff-Hadad, R.A. Beguería, J. Pérez-Nellar, Rodríguez AJ. Colina-.
Lípidos y lipoproteínas en un grupo de pacientes con enfermedad cerebrovascular isquémica.
Rev Neurol, 27 (1998), pp. 804-808
[15.]
M. Nagayama, Y. Shinohara, T. Nagayama.
Lipoprotein(a) and ischemic cerebrovascular disease in young adults.
Stroke, 25 (1994), pp. 74-78
[16.]
G. Jurgens, W.C. Taddei-Peters, P. Koltringer, W. Petek, Q. Chen, J. Greilberger, et al.
Lipoprotein(a) serum concentration and apolipoprotein( a) phenotype correlate with severity and presence of ischemic cerebrovascular disease.
Stroke, 26 (1995), pp. 1841-1848
[17.]
M. Sentí, J. Pedro-Botet, J. Rubiés-Prat, X. Nogués, T. Auguet, J. Roquer, et al.
Influence of apolipoprotein(a) genetic polymorphism on serum lipoprotein(a) concentration in patients with ischemic cerebrovascular disease.
Cerebrovasc Dis, 4 (1994), pp. 298-303
[18.]
S. Shintani, S. Kikuchi, H. Hamaguchi, T. Shiigai.
High serum lipoprotein( a) levels are an independent risk factor for cerebral infarction.
Stroke, 2 (1993), pp. 965-969
[19.]
J. Molgaard, I.C. Klausen, C. Lassvik, O. Faergeman, L.U. Gerdes, A.G. Olsson.
Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication.
Arteriosclerosis and Thrombosis, 12 (1992), pp. 895-901
[20.]
D.N. Kiortsis, G. Turpin.
Action athérogène de la lipoprotéine(a) sur les artères périphériques de sujets hypercholestérolémiques des deux sexes.
Sem Hôp Paris, 75 (1999), pp. 1213-1218
[21.]
A. Dionyssiou-Asteriou, M. Papastamatiou, I. Vatalas, E. Bastounis.
Serum Lp(a) lipoprotein levels in patients with atherosclerotic occlusive disease of the lower extremities.
Eur J Vasc Endovasc Surg, 20 (2000), pp. 57-60
[22.]
J.D. Morrisett.
The role of Lipoprotein[a] in atherosclerosis.
Curr Ather Rep, 2 (2000), pp. 243-250
[23.]
H. Dieplinger, F. Kronenberg.
Genetics and metabolism of lipoprotein( a) and their clinical implications (Part 1.
Wien Klin Wochensch, 111 (1999), pp. 5-20
[24.]
L. Berglund.
Diet and drug therapy for lipoprotein(a.
Current Opinion Lipidol, 6 (1995), pp. 48-56
[25.]
B.O.H. Vessby.
Diet and lipoprotein(a.
Nutr Metab Cardiovasc Dis, 6 (1996), pp. 239-244
[26.]
V. Mijatovic, M.J. van der Mooren, P. Kenemans, G.W. de Valk-de Roo, C. Netelenbos.
Raloxifene lowers serum lipoprotein(a) in healthy postmenopausal women: a randomized, double-blind, placebo- controlled comparison with conjugated equine estrogens.
Menopause, 6 (1999), pp. 34-37
[27.]
A. Estelles, A. Cano, C. Falcó, F. España, J. Gilabert, S. Grancha, et al.
Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause –influence of hormone replacement therapy.
Thromb Haemost, 81 (1999), pp. 104-110
[28.]
I.S. Serin, E.M. Aygen, M. Basbug, R. Saraymen, F. Narin, M. Tayyar.
Continuous versus cyclical transdermal oestrogen replacement therapy in postmenopausal women: effects on lipoprotein( a) and nitric oxide levels.
Aust N Z J Obstet Gynaecol, 41 (2001), pp. 447-449
[29.]
E. Klor, S. Loy, K. Huth.
Effects of etofibrate therapy on high lipoprotein( a) levels in patients with hypercholesterolemia.
Curr Ther Res, 55 (1994), pp. 988-996
[30.]
Second Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection.Evaluation and Treatment of High Blood Cholesterol in Adults.
Jama, 269 (1993), pp. 3015-3023
[31.]
Departamento de investigación clínica de Merz+Co. Lipo-Merz Retard. MERZ Pharma
[32.]
B.G. Jacob, W.O. Richter, P. Schwandt.
Lovastatin, pravastatin and serum lipoprotein(a.
Ann Intern Med, 112 (1990), pp. 713-714
[33.]
P.K. Li, T.W. Mak, K. Chiu, G.Y.K. Mak, C.B. Leung, S.F. Lui, et al.
Effect of lovastatin on serum lipid profile in the treatment of dyslipoproteinaemia in uraemic patients on continuous ambulatory peritoneal dialysis.
Aust N Z J Med, 23 (1993), pp. 252-257
[34.]
J.A. Farmer, L.C. Washington, P.H. Jones, D.R. Shapiro, A.M. Gotto Jr., G. Mantell.
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia.
Clin Ther, 14 (1992), pp. 708-717
[35.]
J.A.F. Ramires, A.P. Mansur, M.C. Solimene, R. Maranhao, D. Chamone, P. da Luz, et al.
Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia.
International J Cardiol, 48 (1995), pp. 115-120
[36.]
P. Chacón, D. López, J. Lima, J. Fernández-Cortijo, C. Pascual, M. Vilardell.
Ausencia de cambios en la concentración de lipoproteína(a) después del tratamiento con lovastatina durante 3 años en pacientes con hipercolesterolemia primaria.
Clin Invest Arterioscler, 7 (1995), pp. 26-32
[37.]
G.M. Kostner, D. Gavish, B. Leopold, K. Bolzano, M.S. Weintraub, J.L. Breslow.
HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.
Circulation, 80 (1989), pp. 1313-1319
[38.]
G. Jurgens, A. Ashy, G. Zenker.
Raised serum lipoprotein during treatment with lovastatin.
Lancet, 1 (1989), pp. 911-912
[39.]
T.P. Leren, I. Hjermann, O.P. Foss, P. Leren, K. Berg.
Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein( a) level in familial hypercholesterolemic subjects.
Clin Investig, 70 (1992), pp. 711-718
[40.]
O. Traindl, S. Reading, M. Franz, B. Watschinger, R. Klauser, H. Pidlich, et al.
Treatment of hyperlipidemic kidney graft recipients with lovastatin: effect on LDL-cholesterol and lipoprotein(a.
Nephron, 62 (1992), pp. 394-398
[41.]
A.S. Dobs, M. Prasad, A. Goldberg, M. Guccione, D.R. Hoover.
Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs.
Cardiovasc Drugs Ther, 9 (1995), pp. 677-684
[42.]
D.R. Illingworth, E.A. Stein, Y.B. Mitchel, C.A. Dujovne, P.H. Frost, R.H. Knopp, et al.
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
Arch Intern Med, 154 (1994), pp. 1586-1595
[43.]
G. Brown, J.J. Albers, S.M. Fisher, S.M. Schaefer, J.T. Lin, C. Kaplan, et al.
Regression of coronary artery disease as a result of intensive lipid- lowering therapy in men with high levels of apolipoprotein B.
N Engl J Med, 323 (1990), pp. 1289-1298
[44.]
O. Wiklund, B. Angelin, S.E Olofsson, M. Eriksson, G. Gager, L. Berglund, et al.
Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolemia.
Lancet, 335 (1990), pp. 1360-1363
[45.]
C. Cobbaert, P. Sergeant, B. Meyens, J. Szecsi, H. Kesteloot.
Time course of serum Lp(a) in men after coronary artery bypass grafting.
Acta Cardiologica, 47 (1992), pp. 529-542
[46.]
F. Umeda, J. Watanabe, K. Inoue, A. Hisatomi, K. Mimura, T. Yamauchi, et al.
Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein(a) in patients with non-insulin dependent diabetes mellitus.
Endocrinol Jpn, 39 (1992), pp. 45-50
[47.]
H.G. Fieseler, V.W. Armstrong, E. Wieland, J. Thiery, E. Schultz, A.K. Walli, et al.
Serum Lp(a) concentrations are unaffected by treatment with HMG-CoA reductase inhibitor pravastatin: results of a 2 years investigation.
Clin Chim Acta, 204 (1991), pp. 291-300
[48.]
G. Barbi, C.N. Corder, E. Koren, W. McConathy, S.Q. Ye, P. Wilson.
Effect of pravastatin and cholestyramine on triglyceride-rich lipoprotein particles and Lp(a) in patients with type II hypercholesterolemia.
Drug Develop Res, 27 (1992), pp. 297-306
[49.]
A. Branchi, A. Rovellini, A.M. Fiorenza, D. Sommariva.
Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein(a) level in hypercholesterolemic patients.
Int J Clin Pharmacol Ther, 33 (1995), pp. 345-350
[50.]
I.C. Klausen, L.U. Gerdes, H. Meinertz, F.A. Hansen, O. Faergeman.
Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.
Eur J Clin Investig, 23 (1993), pp. 240-245
[51.]
C. Wanner, Lubrich-Birkner, O. Summ, H. Weiland, P. Schollmeyer.
Effect of simvastatin on qualitative and quantitative changes of protein metabolism in CAPD patients.
Nephron, 62 (1992), pp. 40-46
[52.]
J. Thiery, V.W. Armstrong, J. Schleef, C. Creutzfeldt, W. Creutzfeldt, D. Seidel.
Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor.
Klin Wochenschr, 66 (1988), pp. 462-463
[53.]
I.F.W. McDowell, M. Smye, T. Trinick, J.A. Shortt, M.P. Archibald, E.R. Trimble, et al.
Simvastatin in severe hypercholesterolaemia: a placebo controlled trial.
Br J Clin Pharmacol, 31 (1991), pp. 340-343
[54.]
L. Slunga, O. Johnson, G.H. Dahlen.
Changes in Lp(a) lipoprotein levels during treatment of hypercholesterolaemia with simvastatin.
Eur J Clin Pharmacol, 43 (1992), pp. 369-373
[55.]
T. Sampietro, F. Galetta, A. Bionda.
Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin.
Cardiovasc Drugs Ther, 9 (1995), pp. 785-789
[56.]
F. Galetta, T. Sampietro, G. Basta, G. Giannasi, A. Bionda.
Effects of simvastatin on blood levels of lipoprotein.
Minerva Med, 86 (1995), pp. 299-303
[57.]
S. Haffner, T. Orchard, E. Stein, D. Schmidt, P. LaBelle.
Effect of simvastatin on Lp(a) concentrations.
Clin Cardiol, 18 (1995), pp. 261-267
[58.]
H. Adamska-Dyniewska, J. Chojnowska-Jezierska.
Effect of oneyear treatment with low simvastatin doses on lipids and Lp(a) in patients with significant hypercholesterolemia.
Pol Arch Med Wewn, 99 (1998), pp. 366-372
[59.]
N. Hoogerbrugge, H. Jansen, L. De Heide, M.C. Zillikens, J.W. Deckers, J.C. Birkenhager.
The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
J Intern Med, 243 (1998), pp. 151-156
[60.]
S.J. Bredie, H.T. Westerveld, H.C. Knipscheer, T.W. de Bruin, J.J. Kastelein, A.F. Stalenhoef.
Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
Neth J Med, 49 (1996), pp. 59-67
[61.]
M. Farnier, F. Bonnefous, N. Debbas, A. Irvine.
Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Arch Intern Med, 154 (1994), pp. 441-449
[62.]
E. Leitersdorf, S. Eisenberg, O. Eliav, V. Friedlander, N. Berkman, E.J. Dann, et al.
Genetic determinants of responsiveness to the HMGCoA reductase inhibitor fluvastatin in patients with molecularly defined hypercholesterolemia.
Circulation, 87(Suppl III (1993), pp. 35-44
[63.]
J.A. Goudevenos, E.T. Bairaktari, K.G. Chatzidimou, H.J. Milionis, D.P. Mikhailidis, M.S. Elisaf.
The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia —A pilot study involving serial sampling.
Curr Med Res and Opin, 16 (2001), pp. 269-275
[64.]
A.G. Fereshetian, M. Davidson, H. Haber, D.M. Black.
Gemfibrozil treatment in patients with elevated lipoprotein(a). A pilot study.
Clin Drug Invest, 16 (1998), pp. 1-7
[65.]
P.H. Jones, H.J. Pownall, W. Patsch, J.A. Herd, J.A. Farmer, C. Payton-Ross, et al.
Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects.
J Lipid Res, 37 (1996), pp. 1298-1308
[66.]
M. Jauhiainen, P. Koskinen, C. Ehnholm, M.H. Frick, M. Manttari, V. Manninen, et al.
Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants.
Atherosclerosis, 89 (1991), pp. 59-67
[67.]
G. Simoni, A. Gianotti, A. Ardia, A. Balardi, D. Civalleri.
Gemfibrozil and mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol-pilot study.
Cardiovasc Drugs Ther, 9 (1995), pp. 347-350
[68.]
A. Bimmermann, C. Boerschmann, W. Schwartzkopff, H. Von Baeyer, J. Schleicher.
Effective therapeutic measures for reducing lipprotein( a) in patients with dyslipidemia. Lipoprotein(a) reduction with sustained-release bezafibrate.
Curr Therap Res, 49 (1991), pp. 635-643
[69.]
F.M. Maggi, M.R. Piglionica, L. De Michele, S. Baroni, G.M. Biasi, A.L. Catapano.
Bezafibrate lowers elevated plasma levels of fibrinogen and lipoprotein(a) in patients with type IIa and b dyslipoproteinaemia.
Nutr Metab Cardiovasc Dis, 4 (1994), pp. 215-220
[70.]
A. Pelegrí, R. Romero, M. Sentí, X. Nogués, J. Pedro-Botet, J. Rubíes-Prat.
Effect of bezafibrate on lipoprotein(a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.
Nephrol Dial Transplant, 7 (1992), pp. 623-626
[71.]
G. Kostner, G. Klein, F. Krempler.
Can serum Lp(a) concentrations be lowered by drugs and/or diet?.
Treatment of hyperlipoproteinemia, pp. 151-156
[72.]
M. Barbir, B. Hunt, S. Kushwaha, A. Kehely, R. Prescot, G.R. Thompson, et al.
Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients.
Am J Cardiol, 70 (1992), pp. 1596-1601
[73.]
Communications au 7.o Congrès de l’EAS. Lipoprotéine Lp(a), athérosclérose et fénofibrate. JAMA 1992;(Suppl a l’édition francaise): 2-4
[74.]
B. Vessby, G. Kostner, H. Lithell, J. Thomis.
Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A doseresponse study of the effects of cholestyramine in hypercholesterolaemia.
Atherosclerosis, 44 (1982), pp. 61-71
[75.]
L.A. Carlson, A. Hamsten, A. Asplund.
Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.
J Int Med, 26 (1989), pp. 271-276
[76.]
F. Lepre, B. Campbell, S. Crane, P. Hickmn.
Low-dose sustained release nicotinic acid (Tri-B3) and lipoprotein(a) [Letter].
Am J Cardiol, 70 (1992), pp. 133
[77.]
M. Seed, B. O’Connor, N. Perombelon, M. O’Donnell, D. Reaveley, B.L. Knight.
The effect of nicotinic acid and acipimox on lipoprotein( a) concentration and turnover.
Atherosclerosis, 101 (1993), pp. 61-68
[78.]
A. Gurakar, J.M. Hoeg, G. Kostner, N.M. Papdopoulos, H.B. Brewer Jr..
Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment.
Atherosclerosis, 57 (1985), pp. 293-301
[79.]
A. Matsunaga, K. Handa, T. Mori, K. Moriyama K Hidaka, N. Yuki, et al.
Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.
Atherosclerosis, 94 (1992), pp. 241-248
[80.]
H. Nakahama, T. Nakanishi, O. Uyama, M. Sugita, M. Miyazaki, T.E. Yokokawa, et al.
Niceritrol reduces plasma lipoprotein(a) levels in patiens undergoing maintenance hemodialysis.
Ren Fail, 5 (1993), pp. 189-193
[81.]
T. Teramoto, N. Yamada, H. Shimano, Y. Oka, H. Itakura, Y. Saito, et al.
Dose-dependent effect of niceritrol on plasma Lipoprotein-a.
Scand J Clin Lab Invest, 56 (1996), pp. 359-365
[82.]
B. Angelin.
Therapy for lowering lipoprotein(a) levels.
Current Opin Lipidol, 8 (1997), pp. 337-341
[83.]
F. Kronenberg, M.F. Kronenberg, S. Kiechl, E. Trenkwalder, P. Santer, F. Oberhollenzer, et al.
Role of lipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study.
Circulation, 100 (1999), pp. 1154-1160
[84.]
G. Lippi, G. Guidi.
Lipoprotein(a) from ancestral benefit to modern pathogen?.
Q J Med, 93 (2000), pp. 75-84
[85.]
M. Alsaeid, M. Al-Essa, K. Alsaeid, P.N. Sharma.
Lipoprotein (a) profiles in Arab newborns.
Pediat Intern, 41 (1999), pp. 65-69
[86.]
W.F. Bremner, R.B. Sothern, E.L. Kanabrocki, M. Ryan, J.B. McCormick, S. Dawson, et al.
Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men.
Am Heart J, 139 (2000), pp. 164-173
[87.]
W. Su, H. Campos, H. Judge, B.W. Walsh, F.M. Sacks.
Metabolism of apo(a) and apo B100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement.
J Clin Endocrinol Metab, 83 (1998), pp. 3267-3276
[88.]
M. Sentí, J. Pedro-Botet, J. Rubíes-Prat, J. Marrugat.
Interrelationship of triglyceride-rich lipoproteins, serum lipoprotein(a) concentration and apolipoprotein(a) size.
Scand J Clin Lab Invest, 56 (1996), pp. 311-318
[89.]
T. Wlek, A. Von Eckardstein, H. Schulte, G. Assmann.
Effect of hypertriglyceridaemia on lipoprotein(a) serum concentrations.
Eur J Clin Investig, 25 (1995), pp. 311-316
[90.]
W. Bartens, D.J. Rader, G. Talley, H.B. Brewer.
Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia.
Atherosclerosis, 108 (1994), pp. 149-157
[91.]
M. Parlavecchia, A. Pancaldi, R. Taramelli, P. Valsania, L. Galli, G. Pozza, et al.
Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men 55 years of age.
Am J Cardiol, 74 (1994), pp. 346-351
[92.]
D.J. Rader, W. Cain, L.A. Zech, D. Usher, B. Brewer Jr..
Variation in lipoprotein( a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein( a) production.
J Clin Invest, 91 (1993), pp. 443-447
[93.]
G.M. Kostner, A. Steinmetz.
Standardization of Lp(a) measurements.
Clin Genet, 52 (1997), pp. 393-397
[94.]
E. Anglés-Cano, S. Loyau, G. Cardoso-Saldaña, R. Couderc, P. Gillery.
A novel kringle-4 number-based recombinant apo[a] standard for human apo[a] phenotyping.
J Lip Res, 40 (2000), pp. 1-6
[95.]
C. Hernández, P. Chacón, L. García-Pascual, J. Rosselló, R. Simó.
Lipoproteína( a) y estimación del colesterol LDL mediante la fórmula de Friedewald: un nuevo problema para una vieja ecuación.
Med Clin (Barc), 113 (1999), pp. 290-291
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.